中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

4 records (took 0.02 seconds)

    Intraperitoneally-administered nanocarriers that release their therapeutic load based on the inflammatory environment of cancers
    1.
    发明专利
    Intraperitoneally-administered nanocarriers that release their therapeutic load based on the inflammatory environment of cancers 未知

    公开(公告)号：AU2012284147A1

    公开(公告)日：2014-02-27

    申请号：AU2012284147

    申请日：2012-07-18

    Applicant: STC UNM

    Inventor： ZEINELDEN REEMA

    IPC: A61K9/16 ,  A61K9/14 ,  A61K9/22 ,  A61K47/30 ,  A61K47/48 ,  A61P35/00

    Abstract: In one embodiment, the invention provides a new design of nanocarrier compositions that release their therapeutic load specifically at intraperitoneal cancers' site. These nanocarriers are administered intraperitoneally and comprise a plurality of porous nanoparticulates that (a) are loaded with one or more pharmaceutically-active agents alone or in combination with imaging agents thus providing a theranostic value and (b) that are encapsulated by and that support a lipid bilayer which is disrupted upon contact with a reactive oxygen species generated within the environment of the cancer. In other embodiments, the invention provides methods of treatment and pharmaceutical compositions comprising nanocarriers as described herein.

    INTRAPERITONEALLY-ADMINISTERED NANOCARRIERS THAT RELEASE THEIR THERAPEUTIC LOAD BASED ON THE INFLAMMATORY ENVIRONMENT OF CANCERS
    3.
    发明专利
    INTRAPERITONEALLY-ADMINISTERED NANOCARRIERS THAT RELEASE THEIR THERAPEUTIC LOAD BASED ON THE INFLAMMATORY ENVIRONMENT OF CANCERS 未知

    公开(公告)号：CA2842306A1

    公开(公告)日：2013-01-24

    申请号：CA2842306

    申请日：2012-07-18

    Applicant: STC UNM

    Inventor： ZEINELDEN REEMA

    IPC: A61K9/16 ,  A61K9/14 ,  A61K9/22 ,  A61K47/30 ,  A61K47/48 ,  A61P35/00

    Abstract: In one embodiment, the invention provides a new design of nanocarrier compositions that release their therapeutic load specifically at intraperitoneal cancers' site. These nanocarriers are administered intraperitoneally and comprise a plurality of porous nanoparticulates that (a) are loaded with one or more pharmaceutically-active agents alone or in combination with imaging agents thus providing a theranostic value and (b) that are encapsulated by and that support a lipid bilayer which is disrupted upon contact with a reactive oxygen species generated within the environment of the cancer. In other embodiments, the invention provides methods of treatment and pharmaceutical compositions comprising nanocarriers as described herein.

Patent Agency Ranking